- One Health
- Pain Management
- Oncology
- Geriatric & Palliative Medicine
- Ophthalmology
- Anatomic Pathology
- Poultry Medicine
- Infectious Diseases
- Dermatology
- Theriogenology
- Nutrition
- Animal Welfare
- Radiology
- Internal Medicine
- Small Ruminant
- Cardiology
- Dentistry
- Feline Medicine
- Soft Tissue Surgery
- Urology/Nephrology
- Avian & Exotic
- Preventive Medicine
- Anesthesiology & Pain Management
- Integrative & Holistic Medicine
- Food Animals
- Behavior
- Zoo Medicine
- Toxicology
- Orthopedics
- Emergency & Critical Care
- Equine Medicine
- Pharmacology
- Pediatrics
- Respiratory Medicine
- Shelter Medicine
- Parasitology
- Clinical Pathology
- Virtual Care
- Rehabilitation
- Epidemiology
- Fish Medicine
- Diabetes
- Livestock
- Endocrinology
Adequan shortage imminent due to FDA-driven factory renovations
Adequan shortage imminent due to FDA-driven factory renovations
Supplies of Adequan i.m., a polysulfated glycosaminoglycan (PSGAG) approved by the Food and Drug Administration (FDA) to treat joint problems in horses, are expected to be limited during the coming months due to renovations at the company’s Shirley, N.Y., manufacturing facility.
“Our factory in N.Y. has undergone a significant renovation to meet enhanced quality standards and address observations of the FDA,” states Luitpold Pharmaceuticals in a May release. “This has resulted in the depletion of our existing inventories. We have carefully managed supply to allocate inventory optimally, but the product will be out of stock for a short period of time.”
Luitpold expects to resume shipments of the 5-ml product in early July, followed by the 50-ml product in August. For updates on expected release dates, visit adequan.com.
